Oasmia reviewing proposals from firms interested in API solubility enchancement tech
Oasmia Pharmaceutical AB has started reviewing ‘term sheets’ from firms interested in its vitamin A-derived drug delivery tech.
Archives for May 30, 2016
Monsanto bid may mean Bayer will cut pharma R&D spending, says analyst
The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.
Granules 483-hit API plant receives all clear from US FDA
A Granules API plant in Hyderabad which received a Form 483 with three observations has been given the all clear by the US FDA.
Clinical grade wearables market to reach $18.9bn by 2020
Clinical grade wearables support “anywhere-anytime” paradigms, allowing clinical trial participants flexibility and CROs better access to data.
Europe OKs Samsung Bioepis’ Remicade biosimilar Flixabi
The European Commission (EC) has approved Samsung Bioepis’ Remicade (infliximab) biosimilar.